Business Description
NFL Biosciences is a French biotechnology company focused on turning plant-based compounds into approved medicines. Its most advanced product, NFL-101, is currently in mid-stage clinical trials as a treatment to help people quit smoking, while a second candidate, NFL-301, aims to reduce alcohol dependence and is still in early research. The company works alongside McLean Hospital to better understand how NFL-101 works in the body. Founded in 2006 and based in Castelnau-le-Lez, NFL Biosciences is building a pipeline centered on natural-origin therapies for behavioral health conditions.
